AbbVie (ABBV) reported Q1 2026 results on April 29, 2026, surpassing Wall Street estimates on both revenue and EPS while raising full-year guidance. Skyrizi and Botox proved to be the primary growth engines, effectively defending against mounting Humira biosimilar pressure.
Key Financial Highlights
AbbVie's Q1 2026 results (January–March) exceeded market expectations on both the top and bottom lines. Adjusted EPS came in 6 cents above consensus, while revenue also topped analyst estimates. Skyrizi, now a cornerstone of AbbVie's immunology portfolio, delivered quarterly revenue of $4.483B, serving as the primary driver of company-wide growth.
- Adjusted EPS: Beat consensus by +6 cents
- Revenue: Exceeded analyst estimates (surprise beat recorded)
- Skyrizi revenue: $4.483B (sustained strong sequential growth)
- Botox sales: Partially offset Humira revenue decline
- Humira: Portfolio-level defense holding despite ongoing biosimilar competition
Guidance & Outlook
Building on Q1's strong performance, AbbVie's management raised its full-year 2026 adjusted EPS guidance. Bloomberg noted that robust Botox sales played a pivotal role in offsetting revenue headwinds from Humira biosimilar penetration. The company expressed confidence that growth momentum from next-generation immunology assets — including Skyrizi and Rinvoq — will carry into the second half of the year. However, some outlets reported that GAAP net income fell short of expectations, prompting calls for closer investor scrutiny of non-recurring expense items.
Market Reaction & Investment Implications
ABBV shares responded positively following the earnings release. GuruFocus noted that the stock remains approximately 1.6% undervalued relative to intrinsic value post-Q1 results. StreetInsider highlighted the trifecta of an EPS beat, revenue outperformance, and upward guidance revision as a clear positive signal. For long-term investors, ABBV is widely regarded as a stable dividend growth stock — the raised guidance reinforces dividend sustainability and enhances its appeal as a core holding. That said, the GAAP earnings miss and Humira's structural long-term decline remain risk factors warranting ongoing monitoring.
